)
Immunocore (IMCR) investor relations material
Immunocore UBS Global Biopharma Conference 2026 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.KIMMTRAK commercial outlook
KIMMTRAK is standard of care across major markets, with 70%+ penetration; growth is moderating as the product matures.
U.S. growth focus: deeper community-setting penetration and patient access; OUS growth mainly from new launches, patient access, and longer treatment duration in newer markets.
Duration of therapy is ~14 months in major markets launched for 4–5 years, versus ~10–11 months in clinical studies; U.S. duration has mostly stabilized.
Uveal melanoma combination and competition
Phase 1/2 study enrolled patients with unresectable or metastatic HLA-A*02:01-positive mUM; brenetafusp monotherapy enrolled 22 patients and combination with tebentafusp enrolled 26; data cutoff was June 2026.
In the 1L combination cohort (n=17), ORR was 29%, DCR 71%, median DOR 24.1 months and PFS 8.1 months; median OS was not reached, with 70% 2-year OS at 29 months’ median follow-up.
Monotherapy evaluable patients (n=16; 2L+) had 19% ORR, 63% DCR, median DOR 14.5 months, PFS 4.2 months and OS 20.3 months; 23% had prior tebentafusp.
TRAEs occurred in 100% of both cohorts; grade 3/4 TRAEs occurred in 45% with monotherapy and 38% with combination. No TRAE led to discontinuation or death; no new combination safety signals were reported.
Dual gp100/PRAME targeting aims to increase tumor engagement and T-cell killing; combination data compared favorably with historical tebentafusp monotherapy datasets in a cross-trial comparison. Randomized evaluation was in planning.
TEBE-AM in advanced cutaneous melanoma
Phase III TEBE-AM tests KIMMTRAK plus pembrolizumab in refractory advanced cutaneous melanoma; rationale includes GP100 expression of 85%+ in uveal and cutaneous tumors and activity of both agents.
Enrollment completed in the prior quarter; OS-driven results are expected in Q2 2027. Management advised against reading into the timing shift because the study is blinded.
Eligible patients must have failed ipilimumab/nivolumab and, if BRAF-mutant eligible, BRAF therapy; control allows locally available treatment, including retreatment, chemotherapy, palliative care or trials.
Expected control-arm OS is ~10–11 months based on real-world treatment mix; management said a statistically significant OS benefit would support commercial prospects.
- KIMMTRAK growth anchors a pipeline spanning cancer, HIV and autoimmune disease.IMCR
Corporate presentation - 9M KIMMTRAK sales rose 9.9%; TEBE-AM topline data are expected in Q2 2027.IMCR
Q3 2026 - AI-driven R&D and robust clinical progress position the pipeline for significant near-term expansion.IMCR
Morgan Stanley 24th Annual Global Healthcare Conference - Phase III trials near key readouts as KIMMTRAK drives growth and pipeline expansion.IMCR
12th Annual Cantor Fitzgerald Global Healthcare Conference - Expanding TCR therapies drive survival gains in melanoma and advance into HIV and autoimmunity.IMCR
Corporate presentation - H1 2026 revenue up 16% to $223M, net income $12.2M, and pipeline advances continue.IMCR
Q2 2026 - Strong TCR innovation, expanding pipeline, and disciplined growth drive future opportunities.IMCR
Morgan Stanley 23rd Annual Global Healthcare Conference - Strong pipeline progress and high-margin growth set up major data catalysts in the next 18 months.IMCR
TD Cowen 45th Annual Healthcare Conference - KIMMTRAK posts strong growth and pipeline advances, with pivotal trial readouts expected soon.IMCR
Jefferies Global Healthcare Conference 2025
)
)
)
)
)
)
)
)